重组人血管内皮抑制素致中毒性表皮坏死松解症

Recombinant human endostatin‑induced toxic epidermal necrolysis

1例59岁男性患者因肺低分化腺癌伴脑转移给予靶向药物重组人血管内皮抑制素注射液15 mg静脉滴注、1次/d,连续14 d。停药第17天,患者颈部和胸部出现红斑、瘙痒,随后红斑迅速扩散至全身,并出现水疱和广泛的表皮脱落,伴有瘙痒、疼痛和低热。考虑为重组人血管内皮抑制素导致的中毒性表皮坏死松解症。给予大剂量糖皮质激素和人免疫球蛋白治疗,2周后,皮损基本愈合。

A 59‑year‑old male patient received targeted drug recombinant human endostatin injection 15 mg intravenously once daily for 14 days for poorly differentiated adenocarcinoma of lung with brain metastasis.On the 17th day after drug withdrawal,erythema and pruritus appeared on the neck and chest,and then the erythema quickly spread to the whole body,with blisters and extensive epidermal exfoliation,accompanied by pruritus,pain,and mild fever.Toxic epidermal necrolysis caused by recombinant human endostatin was considered.High‑dose of glucocorticoid and human immunoglobulin were given and 2 weeks later,the skin lesions healed basically.